ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: FR-OR111

Aldosterone Synthase Inhibition with or Without Background Sodium Glucose Cotransporter 2 Inhibition in CKD: A Phase II Clinical Trial

Session Information

Category: CKD (Non-Dialysis)

  • 2302 CKD (Non-Dialysis): Clinical, Outcomes, and Trials


  • Tuttle, Katherine R., University of Washington, Seattle, Washington, United States
  • Hauske, Sibylle Jenny, Boehringer Ingelheim International GmbH, Ingelheim, Rheinland-Pfalz, Germany
  • Cronin, Lisa, Boehringer Ingelheim International GmbH, Ingelheim, Rheinland-Pfalz, Germany
  • Sun, Zhichao, Boehringer Ingelheim International GmbH, Ingelheim, Rheinland-Pfalz, Germany
  • de Zeeuw, Dick, Universitair Medisch Centrum Groningen, Groningen, Groningen, Netherlands
  • Heerspink, Hiddo Jan L., Universitair Medisch Centrum Groningen, Groningen, Groningen, Netherlands
  • Rossing, Peter, Steno Diabetes Center Copenhagen, Herlev, Capital Region, Denmark

Group or Team Name

  • On behalf of the Steering Committee

High aldosterone levels accelerate chronic kidney disease (CKD) progression. We tested the efficacy and safety of BI 690517, a novel aldosterone synthase inhibitor (ASI), in participants (pts) with CKD.


In this double-blind trial (NCT05182840), adults with CKD on a renin angiotensin system inhibitor (RASi) were first randomized (R1) 1:1 to an 8-week run-in to background (BG) empagliflozin 10 mg (EMPA) or placebo (PBOEMPA) and then randomized a second time (R2) 1:1:1:1 to BI 690517 (3, 10, or 20 mg) or PBOASI. The primary endpoint was change from R2 baseline (BL) in urine albumin:creatinine ratio (UACR) from the first morning void at Week 14. A secondary endpoint was UACR ≥30% reduction from R2 BL at Week 14.


Of 714 pts randomized in R1, 586 were randomized in R2. At R2 BL, mean (SD) age was 63.8 (11.3) years, 58.4% of pts were White, 66.6% were male, and 70.6% had type 2 diabetes. BL median (IQR) UACR was 426.3 (205–889) mg/g and mean (SD) eGFR was 51.9 (17.7) mL/min/1.73m2. BI 690517 dose dependently reduced UACR (Figure). Largest median (95% CI) PBOASI-corrected change was −39.5% (−51.8, −24.0) for BI 690517 10 mg on EMPA BG. Among BI 690517 3–20mg pts, changes in UACR ≥30% were achieved by 53.5% on EMPA BG and 43.2% on PBOEMPA BG. BI 690517 (3–20mg)-related adverse events were reported in 19.2% of pts on EMPA BG and 18.5% of those on PBOEMPA BG.


BI 690517 was well tolerated and dose dependently reduced UACR on top of BG RASi and EMPA/PBOEMPA in pts with CKD. BI 690517 and EMPA showed additive anti-albuminuric efficacy that may translate into greater kidney protection.

Percentage change from R2 BL in UACR up to Week 14 following BI 690517 treatment administered with A) EMPA-matched placebo or B) EMPA 10 mg.


  • Commercial Support – Boehringer Ingelheim